Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company's portfolio includes idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) diseases. The company develops C21, a low molecular weight angiotensin II type 2 receptor agonist ATRAG; Almee, an investigational medical device in clinical development to address the psychological impact of living with pulmonary fibrosis; Inhaled IMID for the severe cough associated with IPF; and C103, C111, and C112.

It has a collaboration and development agreement with Emeriti Bio AB. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is based in Stockholm, Sweden.